アクセスを改善するためのリモート妊娠モニタリング (REACTIVE)
アクセスを改善するためのリモート妊娠モニタリング: REACTIVE 試験
The goal of this clinical trial is to determine the effectiveness of remote nonstress test (NST) compared to in-clinic NSTs in improving fetal testing completion rates. Participants will be randomized to either in-clinic NSTs or use of an FDA-approved remote monitoring belt for their pregnancy monitoring.
調査の概要
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19104
- University of Pennsylvania
-
-
参加基準
適格基準
就学可能な年齢
- 子
- 大人
- 高齢者
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Singleton pregnancy
- Gestational age between 30 weeks 0 days and 35 weeks 6 days
- Pregnant patients who have clinical indication for fetal surveillance with NSTs (based on UPHS Health System clinical guidelines for antenatal monitoring)
- Able to provide written consent
- English speaking
Exclusion Criteria:
- Multiple gestations
- Maternal pre-gravid BMI greater than 45kg/m2
- Presence of an implanted pacemaker or defibrillator
- Active abdominal skin infection
- A known amniotic fluid index (AFI) less than 5cm or greater than 25cm on the most recent ultrasound (if available) prior to randomization
- Delivery is planned within 2 weeks of potential randomization
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:診断
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:リモートNST
|
INVU monitoring belt used for remote NSTs |
|
アクティブコンパレータ:クリニックでのNST - 標準治療
|
In-clinic NSTs - standard of care |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Fetal Testing Completion Rate
時間枠:from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.
|
Percentage of recommended antenatal testing sessions successfully completed, defined as a clinically interpreted test performed. Calculated for each participant as: number of NST visits completed divided by number of NST visits expected × 100. |
from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.
|
|
Fetal Testing Completion Rate in Black Versus Non-Black Subjects
時間枠:from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.
|
Comparison between Black and non-Black subjects' percentage of recommended antenatal testing sessions that were successfully completed as defined as a clinically interpreted test was performed. Calculated as the number of NST visits completed divided by the number of NST visits expected per participant × 100. |
from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Fetal Monitoring Outcomes: Number of Visits to the Antenatal Testing Unit
時間枠:from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.
|
Count of visits to the office for in-person monitoring |
from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.
|
|
Fetal Monitoring Outcomes: Percentage of Non-Stress Test Sessions Requiring Provider-Recommended Prolonged Monitoring
時間枠:From randomization until delivery.
|
For each participant, the percentage of all NST sessions requiring prolonged monitoring (>40 minutes) was calculated. The median participant-level percentage is reported. |
From randomization until delivery.
|
|
Fetal Monitoring Outcomes: Average Duration of Non-Stress Test Monitoring Sessions
時間枠:From randomization until delivery.
|
Mean duration of NST monitoring sessions across all NSTs completed by each participant from randomization to delivery. Participant-level means were calculated and summarized by study arm. |
From randomization until delivery.
|
|
Fetal Monitoring Outcomes: Non-reactive NST Rate
時間枠:From randomization until delivery
|
Percentage of NSTs that were non-reactive among all NSTs completed for each participant. |
From randomization until delivery
|
|
Fetal Monitoring Outcomes: Percentage of NSTs Resulting in Biophysical Profile Evaluation
時間枠:From randomization until delivery.
|
Percentage of completed NSTs followed by biophysical profile assessment. |
From randomization until delivery.
|
|
Fetal Monitoring Outcomes: Number of Participants With ≥1 Obstetrical Triage Visit
時間枠:From randomization to delivery
|
Number of Participants With ≥1 Obstetrical Triage Visit |
From randomization to delivery
|
|
Fetal Monitoring Outcomes: Number of Participants Who Had Any Triage Visit Directly Related to a Fetal Monitoring Visit
時間枠:From randomization to delivery
|
Number of participants who underwent at least one obstetrical triage evaluation directly related to a fetal monitoring visit, during the study period from randomization until delivery. |
From randomization to delivery
|
|
Fetal Monitoring Outcomes: Number of Participants Recommended for Delivery Based on Findings on Fetal Monitoring Result
時間枠:From randomization to delivery
|
Count of the number of subjects in each arm who receive a recommendation for delivery based on the findings of the fetal monitoring results. |
From randomization to delivery
|
|
Fetal Monitoring Outcomes: Percentage of NSTs Not Completed Within the Prescribed Window
時間枠:from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.
|
Percentage of NSTs which occur outside of prescribed window, for example, if a weekly testing regimen is prescribed, an appointment 8 or more days following the last one would count as 1 missed calendar window. |
from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.
|
|
Obstetrics Outcomes: Gestational Age at Delivery
時間枠:time of delivery
|
gestational age at time of delivery |
time of delivery
|
|
Obstetrics Outcomes: Number of Participants With Preterm Delivery
時間枠:time of delivery
|
preterm delivery is defined as less than 37 weeks gestational age |
time of delivery
|
|
Obstetrics Outcomes: Mode of Delivery
時間枠:time of delivery
|
categorized as vaginal or cesarean |
time of delivery
|
|
Obstetrics Outcomes: Number of Participants With an Indication for Labor Induction
時間枠:time of labor induction
|
in subjects who have labor induction, indication for inducing labor |
time of labor induction
|
|
Obstetrics Outcomes: Number of Participants With an Indication for Cesarean Section
時間枠:time of delivery
|
in subjects who have a cesarean section delivery, indication for cesarean section |
time of delivery
|
|
Obstetrics Outcomes: Number of Participants With Composite Neonatal Morbidity
時間枠:from delivery to 6 weeks post-delivery
|
Number of participants whose neonate experienced at least one component of the composite neonatal morbidity outcome, defined as severe respiratory distress, neonatal resuscitation outside the delivery room, or neonatal death. |
from delivery to 6 weeks post-delivery
|
|
Obstetrics Outcomes: Neonatal Cord Blood pH
時間枠:time of delivery
|
time of delivery
|
|
|
Obstetrics Outcomes: Apgar Scores
時間枠:one and five minutes after delivery
|
Apgar score at 1 and 5 minutes after delivery. Scores range from 0 to 10, with higher scores indicating better neonatal condition |
one and five minutes after delivery
|
|
Obstetrics Outcomes: Number of Participants With an Admission to the Neonatal Intensive Care Unit
時間枠:from delivery to 6 weeks post-delivery
|
from delivery to 6 weeks post-delivery
|
|
|
Obstetrics Outcomes: Number of Participants Who Had an Admission to the Neonatal Intensive Care Unit for Greater Than 48 Hours
時間枠:from delivery to 6 weeks post-delivery
|
from delivery to 6 weeks post-delivery
|
|
|
Obstetrics Outcomes: Maternal Length of Hospital Stay
時間枠:Delivery hospitalization
|
Length of maternal hospitalization associated with the delivery admission, measured from hospital admission for delivery through maternal discharge. |
Delivery hospitalization
|
|
Obstetrics Outcomes: Neonatal Length of Hospital Stay
時間枠:Birth hospitalization
|
Length of neonatal hospitalization from birth through hospital discharge. |
Birth hospitalization
|
|
Cost-effectiveness Outcomes: Productivity Loss Due to Antenatal Testing and Monitoring
時間枠:From randomization until delivery (approximately 10 weeks on average)
|
Productivity loss was assessed by summing the number of days of work missed reported by participants across the two study productivity assessments. The reported value represents the total number of work days missed during the study period for each participant. |
From randomization until delivery (approximately 10 weeks on average)
|
|
Cost-effectiveness Outcomes: Total Societal Perspective Cost
時間枠:Randomization through delivery
|
Total societal perspective cost per participant, calculated as the sum of direct healthcare costs, informal healthcare costs, and productivity costs incurred from randomization through delivery. Costs are reported in U.S. dollars (USD). The societal perspective includes costs related to antenatal testing, delivery hospitalization, neonatal care, triage visits, antepartum admissions, productivity losses, caregiving, and transportation. |
Randomization through delivery
|
|
Implementation Outcomes: Theory-informed Acceptability Questionnaire
時間枠:at time of delivery
|
Participant acceptability of the assigned fetal monitoring strategy was assessed using an 8-item Theory-Informed Acceptability Questionnaire (TFA). Total scores range from 8 to 40, with higher scores indicating greater acceptability of the monitoring approach. |
at time of delivery
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 852291
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。